Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 1/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA7 | P43166 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4028881 | 0.88 | THRB (0.47) | HSD17B3PAX8ESR1CA12CA1 | |
| SCHEMBL22420504 | 0.88 | CA12 (0.56) | HSD17B3PAX8ESR1CA12CA1 | |
| SCHEMBL4623313 | 0.86 | HSD17B3 (0.62) | HSD17B3HDAC8HDAC6MAOBCRHBP | |
| SCHEMBL4623310 | 0.86 | HSD17B3 (0.62) | HSD17B3HDAC8HDAC6MAOBCRHBP | |
| SCHEMBL4055668 | 0.84 | CA12 (0.53) | NR1H4ESR1CA12CA1CA2 | |
| SCHEMBL4055672 | 0.84 | CA12 (0.53) | NR1H4ESR1CA12CA1CA2 | |
| SCHEMBL13845314 | 0.84 | CA12 (0.53) | NR1H4ESR1CA12CA1CA2 | |
| SCHEMBL470988 | 0.84 | PAX8 (0.44) | HSD17B3PAX8CYP1A2BRD4CREBBP | |
| SCHEMBL5700803 | 0.83 | LMNA (0.53) | PAX8NR1H4CA12CA7CA9 | |
| SCHEMBL3213923 | 0.82 | AKR1B1 (0.56) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1177181-B1 | SUBSTITUTED BICYCLIC COMPOUNDS | AVENTIS PHARMA LTD (GB) | 2009-01-28 | — | — | EP | disclosed |
| US-6562851-B2 | Antiinflammatory and antiasthmatic agents; inhibitors of alpha4 beta1 mediated cell adhesion | AVENTIS PHARMA LIMITED (GB) | 2003-05-13 | — | — | US | disclosed |
| US-20020156111-A1 | Substituted bicyclic compounds | AVENTIS PHARMA LIMITED (GB) | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156111-A1 | Substituted bicyclic compounds | VCAM1, ITGA1, ITGA5 | HSD17B3 903/4885PAX8 2513/4885NR1H4 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.